Iisrael - heebrea - Ministry of Health

megapharm ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 500 iu - coagulation factor vii

Iisrael - heebrea - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה מיובשת בהקפאה להזרקה - moroctocog alfa 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

Iisrael - heebrea - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

Iisrael - heebrea - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

Iisrael - heebrea - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose 250 iu/vial - powder for solution for injection - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.

Iisrael - heebrea - Ministry of Health

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab

Iisrael - heebrea - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Iisrael - heebrea - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.

Iisrael - heebrea - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Iisrael - heebrea - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa